Compare Abbott Laboratories (ABT) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs SkyWest Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while SkyWest Inc trades at $96.89 (market cap $3.88B). The key difference: Abbott Laboratories is far larger — about 43× SkyWest Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| ABT | SKYW | |
|---|---|---|
Market Cap | $166.94B | $3.88B |
Sector | Health | Technology |
52-Week High | $136.62 | $123.72 |
52-Week Low | $82.57 | $78.40 |
Enterprise Value | $193.69B | $5.73B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
SkyWest (SKYW) trades at $98.75, up 1.93% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 9.47 and P/S of 0.99, while maintaining strong profitability with 10.42% net margin and 16.5% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains stable revenue around $4.1B with consistent cash flow generation from operations exceeding $900M annually.
The outlook remains positive with 56% analyst buy ratings and $109.33 consensus price target suggesting 11% upside. Key risks include rising fuel costs impacting airline profitability and negative net cash flow trends. The upcoming Q2 2026 earnings call on July 23 will be crucial for confirming growth trajectory amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
